Structural Heart

Older Patients and Asymptomatic Valvular Heart Disease

A new study out of the UK found that over a quarter of people aged 60+ have asymptomatic valvular heart disease, and revealed that prevalence increases as patients age — potentially providing new reasons to screen older patients for VHD.

  • VHD diagnosis generally involves echo exams, ordered in response to patient symptoms or abnormal cardiac auscultation.
  • However, this practice leaves many older patients with undetected VHD, raising interest in using echocardiography as a large-scale VHD screening tool.

To test that theory, researchers performed echo exams on 4,237 asymptomatic 60-and-over adults between 2007 and 2016, finding that…

  • A whopping 28.2% of participants had VHD
  • 2.4% of the VHD cases were clinically significant, including 94 moderate cases and 7 severe cases.
  • Significant VHD prevalence increased with age: 1.5% at 60-64yrs, 2.1% at 70-74yrs, 3.8% at 75-79yrs, and 10% at 85+.
  • The most common VHD cases were tricuspid (13.8%), mitral (12.8%), and aortic (8.3%) regurgitation.

Perhaps most actionable, age was the only factor associated with severe VHD (odds ratio: 1.07 per year), with the number of echo scans required to diagnose one clinically significant VHD case falling from 42 scans among 60-74yr olds to 15 scans among 75-and-over patients. 

Age-targeted VHD echo screening might result in even more positive cases in the real world, noting that only 8.6% of this study’s population was ≥80 years old, and other studies have found 51% prevalence of any VHD among over-65 patients and 17% prevalence of moderate-to-severe VHD among 80-and-over patients.

The Takeaway

By 2050 the over-60 population is expected to double, while the over-80 population triples. That elderly population surge will apparently come with a similar surge in undiagnosed VHD cases, unless there’s big changes to how we screen for VHD.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!